The global demand for effective cancer treatments continues to drive the need for high-quality pharmaceutical intermediates. Erlotinib, a vital tyrosine kinase inhibitor, is one such medication, and its production relies on the consistent availability of its precursor, 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone (CAS: 179688-29-0). NINGBO INNO PHARMCHEM CO.,LTD., as a leading manufacturer and supplier from China, plays a critical role in meeting this global demand by providing this essential compound.

NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to ensuring a stable and reliable supply chain for 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone. Our manufacturing capabilities are geared towards producing this intermediate in quantities that meet the needs of pharmaceutical companies worldwide. We understand that the price and timely delivery of such intermediates are crucial for the successful production of APIs like Erlotinib. Therefore, we focus on optimizing our synthesis processes to be both efficient and cost-effective, allowing us to offer competitive pricing without compromising on the ≥99.0% purity that is standard for our product.

The properties of 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone, including its white solid form and defined melting point, make it suitable for global distribution and use in diverse manufacturing settings. As a reputable Chinese supplier, NINGBO INNO PHARMCHEM CO.,LTD. adheres to international quality standards, ensuring that our product meets the rigorous requirements of pharmaceutical clients across different regions. Our commitment extends beyond just providing the chemical; we aim to foster strong partnerships by offering responsive customer service and technical support.

For companies looking to secure their supply of 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone, choosing a trusted manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. is essential. We contribute to the global fight against cancer by ensuring the availability of critical pharmaceutical building blocks, thereby supporting the production of life-saving Erlotinib.